The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: Emerging options

被引：22

作者：

Agnelli, Giancarlo

Caprini, Joseph A.

机构：

[1] Univ Perugia, Dipartimento Med Interna, Sez Med Interna & Cardiovascolare, Stroke Unit & Cardiovasc Med, I-06126 Perugia, Italy

[2] Evanston NW Healthcare, Dept Surg, Evanston, IL USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Evanston, IL 60208 USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2007年 / 96卷 / 03期

关键词：

VTE prophylaxis; cancer; abdominal surgery; factor Xa inhibitors;

D O I：

10.1002/jso.20808

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer is a risk factor for venous thromboembolism (VTE). This risk is amplified by treatment with chemotherapy, radiation, or surgery. Thus, patients with cancer undergoing major surgery should receive appropriate prophylaxis. Available agents include low-dose unfractionated heparin (LDUH), low-molecular-weight heparin (LMWH), and Factor Xa inhibitors. Recent data suggest that Factor Xa inhibitors are safe and effective for VTE prevention in patients with cancer undergoing abdominal surgery. Further study in this patient population is warranted.

引用

页码：265 / 272

页数：8

共 57 条

[1] Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].

Agnelli, G ;

Bergqvist, D ;

Cohen, AT ;

Gallus, AS ;

Gent, M .

BRITISH JOURNAL OF SURGERY, 2005, 92 (10) :1212-1220

[2]

Agnelli G, 2003, BLOOD, V102, p15A

[3]

ALTINBAS M, 2001, J CLIN ONCOL, V20, pA321

[4] LOW-MOLECULAR-WEIGHT HEPARIN STARTED BEFORE SURGERY AS PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS - 2500 VERSUS 5000 XAI UNITS IN 2070 PATIENTS [J].

BERGQVIST, D ;

BURMARK, US ;

FLORDAL, PA ;

FRISELL, J ;

HALLBOOK, T ;

HEDBERG, M ;

HORN, A ;

KELTY, E ;

KVITTING, P ;

LINDHAGEN, A ;

LJUNGSTROM, KG ;

MATZSCH, T ;

RISBERG, B ;

SYK, I ;

TORNGREN, S ;

WELLANDER, E ;

ORTENWALL, P .

BRITISH JOURNAL OF SURGERY, 1995, 82 (04) :496-501

[5]

Bergqvist D, 1997, BRIT J SURG, V84, P1099

[6] Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. [J].

Bergqvist, D ;

Agnelli, G ;

Cohen, AT ;

Eldor, A ;

Nilsson, PE ;

Le Moigne-Amrani, A ;

Dietrich-Neto, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :975-980

[7] RECOMBINANT TUMOR-NECROSIS-FACTOR INDUCES PROCOAGULANT ACTIVITY IN CULTURED HUMAN VASCULAR ENDOTHELIUM - CHARACTERIZATION AND COMPARISON WITH THE ACTIONS OF INTERLEUKIN-1 [J].

BEVILACQUA, MP ;

POBER, JS ;

MAJEAU, GR ;

FIERS, W ;

COTRAN, RS ;

GIMBRONE, MA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4533-4537

[8]

BRADNER J, 2004, BLOOD, V104, P1775

[9] Special considerations with fondaparinux therapy: Heparin-induced thrombocytopenia and wound healing [J].

Dager, WE ;

Andersen, J ;

Nutescu, E .

PHARMACOTHERAPY, 2004, 24 (07) :88S-94S

[10] Cancer and thrombosis: Mechanisms and treatment [J].

Deitcher, SR .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2003, 16 (1-2) :21-31

← 1 2 3 4 5 6 →